• CalendarOctober 30, 2018 – "Obviousness Standard: Leveraging Latest PTO and Court Guidance — Overcoming Challenges of Obviousness and Attacks on Patent Validity" (Strafford) – 1:00 to 2:30 pm (EDT)

    October 30, 2018 – European biotech patent law update (D Young & Co) – 5:00 am, 8:00 am, and 1:00 pm (EDT)

    October 30, 2018 – "University Technology Transfer and Licensing Agreements — Determining Type of Transfer Agreement to Use, Structuring Key Provisions, Overcoming Unique Challenges" (Strafford) – 1:00 to 2:30 pm (EDT)

    October 31, 2018 – "AIA Estoppel: A New Flavor of Collateral Estoppel and/or Res Judicata?" (Intellectual Property Owners Association) – 2:00 to 3:00 pm (ET)

    November 1, 2018 – "When Patents Go Wrong . . . And What To Do About It" (J A Kemp) – 3:30 to 4:30 pm (Greenwich Mean Time)

    November 7, 2018 – "Antibody Patenting After Amgen v. Sanofi: U.S. and European Perspectives — Meeting Written Description and Obviousness Requirements" (Strafford) – 1:00 to 2:30 pm (EST)

    November 8, 2018 – "Deciphering the PTAB's Standard Operating Procedure Changes: A Game Changer for Post-Grant Proceedings" (Technology Transfer Tactics) – 1:00 pm to 2:00 pm (ET)

  • IPO #2The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "AIA Estoppel: A New Flavor of Collateral Estoppel and/or Res Judicata?" on October 31, 2018 from 2:00 to 3:00 pm (ET).  Herbert Hart of McAndrews of Held & Malloy, Ltd. will moderate a panel consisting of Emily Johnson of Amgen Inc.; Barbara McCurdy of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP; and the Hon. James Peterson, Chief District Judge, U.S. District Court for the Western District of Wisconsin.  The panel will explore the potential impact of statutory and rule-based estoppel resulting from Final Written Decisions of the Patent Trial and Appeal Board, including:

    • What is the likely impact of AIA estoppel at the PTAB and in the district courts?
        – Is Shaw still alive after SAS?
        – What's the likely impact of SAS on the scope of estoppel?
        – How does the Maxlinear decision change the potential scope of estoppel?
    • How should the terms "skilled searcher," "diligent search," and "reasonably could have been expected to discover" be interpreted for estoppel purposes?
    • How should non-documentary prior art be handled in a district court, even if it relates to publications used in an IPR?
    • When and how should the estoppel defense be raised at the PTAB? In a district court?

    The registration fee for the webinar is $135 (government and academic rates are available upon request).  Those interested in registering for the webinar can do so here.

  • Technology Transfer Tactics will be offering a webinar entitled "Deciphering the PTAB's Standard Operating Procedure Changes: A Game Changer for Post-Grant Proceedings" on November 8, 2018 from 1:00 pm to 2:00 pm (ET).  Tyson Benson of Harness, Dickey & Pierce, PLC will address revisions to the PTAB's Standard Operating Procedures ("SOPs") relating to paneling of matters before the PTAB and precedential and informative decisions.  The presentation will also cover the following topics:

    • Understanding the revisions to SOP1 that explains the revised procedures for panel assignment;
    • The process for designating panels with more than three judges;
    • Revisions to SOP2 that creates a Precedential Opinion Panel (POP);
    • Understanding the functionality of the POP;
    • Potential impact on licensing and patent value;
    • Best practices for TTOs and attorneys when:
        – Preparing initial patent claims
        – Preparing for:
            inter partes reviews
            post-grant reviews
            covered business method patent reviews
            derivation proceedings

    The registration fee for the webinar is $197.  Those interested in registering for the webinar, can do so here.

    Technology Transfer Tactics

  • J A KempJ A Kemp will be offering a webinar entitled "When Patents Go Wrong . . . And What To Do About It" on November 1, 2018 from 3:30 to 4:30 pm (Greenwich Mean Time).  Andy Bentham of J A Kemp will look at grace periods worldwide in relation to inventor disclosures, restoration of priority, late national phase entry and other "restoration" situations relating to missed renewal fee payments and other deadlines, and also consider how to adapt your filing strategy to account for different scenarios that may arise as a result of missed deadlines.

    Those wishing to register can do so here.

  • Strafford #1Strafford will be offering a webinar entitled "Antibody Patenting After Amgen v. Sanofi: U.S. and European Perspectives — Meeting Written Description and Obviousness Requirements" on November 7, 2018 from 1:00 to 2:30 pm (EST).  Hazel Ford of Mathys & Squire, and Jeffrey M. Jacobstein and Amanda K. Murphy of Finnegan Henderson Farabow Garrett & Dunner will provide guidance to patent counsel on the patentability requirements in the USPTO and EPO for claiming a broad genus of antibodies, recent case law that could impact those claims, and how to best protect antibody inventions in light of the recent developments.  The webinar will review the following issues:

    • How broadly can the applicant claim? How much support is needed on a filing?
    • What are the differences between U.S. requirements and EPO requirements?
    • What is a sufficient description of a genus? Can functional language be included?
    * When can post-filing data be used?

    The registration fee for the webcast is $297.  Those interested in registering for the webinar, can do so here.

  • By Donald Zuhn –-

    USPTO Introduces New Homepage

    USPTO HomepageIn a USPTO Alert e-mail distributed today, the U.S. Patent and Trademark Office announced the release of a new homepage, which the Office indicated was "part of a larger effort to improve the public's online experience with our agency."  The Office noted that the new homepage includes features that had been requested by stakeholders and incorporates input from the Patent and Trademark Public Advisory Committees and the independent inventor community.  Two features of the new homepage highlighted by the Office are "Find It Fast" menus and a mobile-friendly version.


    USPTO Announces Start of Phase 1 of Access to Relevant Prior Art Initiative

    In a Patent Alert e-mail distributed today, the U.S. Patent and Trademark Office announced that Phase 1 of the Office's Access to Relevant Prior Art Initiative will begin on November 1.  The Access to Relevant Prior Art (RPA) Initiative is an effort by the Office to increase patent examination quality and efficiency through the development of an automated tool for USPTO examiners, which will import relevant prior art and other pertinent information from sources such as related U.S. applications, counterpart foreign applications, and International (PCT) applications into pending U.S. patent applications as early as possible in prosecution.  The Office envisions the RPA initiative as a way "to potentially reduce the burden on applicants with complying with the duty of disclosure."

    2018 Access to Relevant Prior ArtIn Phase 1 of the RPA initiative, information in the form of citations on PTO/SB/08 and PTO-892 forms from the immediate parent application will be imported into the continuing application for consideration by the Examiner.  The Office noted that Phase 1 would be limited to select art units — in particular, Art Unit 2131 in Technology Center 2100, with a wider release to Art Units 1616, 1731, 2431, 2675, 2879, 2922, 3635, and 3753 on January 1, 2019.  Applicants will receive a Notice of Imported Citations from the Office informing the applicant that an application has been included in the Initiative and listing the citations from the immediate parent application that have been imported into the application.

    Additional information regarding the RPA initiative can be found at the Office's Access to Relevant Prior Art Initiative webpage.


    USPTO Reminds Users of New Authentication System for EFS-Web and Private PAIR

    EFS-WebIn a Patent Alert e-mail distributed last week, the U.S. Patent and Trademark Office reminded users that the Office has moved to a "new, safer, and simpler" login for EFS-Web and Private PAIR.  The Office also reminded users that a new sponsorship tool will be available for registered practitioners to sponsor their support staff, who work on their behalf, in November.  The Office noted that it would "no longer support the existing public key infrastructure (PKI) certificates for two-factor authentication because the PKI authentication software vendor will no longer support the product after 2018."

    For users having problems migrating to the new authentication system, we recommend specifically following all eight steps listed under the "Migrate your PKI Certificate" tab at the Office's authentication change webpage to link a USPTO.gov account to a user's PKI certificate.  Those steps are reproduced below:

    1.  Opt-in for two-step authentication for your USPTO.gov account.
    2.  Clear your browser cache.
    3.  Close all browsers.
    4.  Go to the Migration Tool.
    5.  Sign in using your PKI digital certificate and review the Account Linking information.
    6.  Sign in using your USPTO.gov account, and confirm that both the PKI digital certificate and USPTO.gov account are verified.
    7.  Review account linking information for accuracy and provide your signature. Click on "Link accounts" to complete migration and link your PKI digital certificate to your USPTO.gov account.
    8.  Please wait 1-2 business days for your account migration to be processed by USPTO before using your USPTO.gov account to sign into EFS-Web and Private PAIR. Please note that you will need to update your bookmarks to the new EFS-Web and Private PAIR URLs for signing in with your USPTO.gov account.

    We also recommend referring to the Office's Guide for Migration (which contains some helpful screenshots) while completing the migration process.


    USPTO Extends After-Final Consideration Pilot 2.0 Program

    USPTO SealIn a Patent Alert e-mail distributed earlier this month, the U.S. Patent and Trademark Office announced that the After-Final Consideration Pilot 2.0 (AFCP 2.0) program has been extended to September 30, 2019.

    The AFCP, which was implemented in April 2012 (see "USPTO to Assess After Final Consideration Pilot Program"), modified in May 2013 (see "USPTO News Briefs"), and extended since then provides examiners with a limited amount of non-production time — three hours for utility and reissue applications — to consider responses filed following a final rejection.  The requirements for participating in the AFCP 2.0 are as follows:

    (1) a transmittal form that requests consideration under AFCP 2.0 (the Office suggests that applicants use form PTO/SB/434);
    (2) a response under 37 CFR 1.116, including an amendment to at least one independent claim that does not broaden the scope of the independent claim in any aspect;
    (3) a statement that the applicant is willing and available to participate in any interview initiated by the examiner concerning the accompanying response (according to the Office, "willing and available" means that the applicant is able to schedule the interview within ten (10) calendar days from the date the examiner first contacts the applicant);
    (4) any necessary fees (e.g., a request filed more than three months after the mailing of a final rejection must include the appropriate fee for an extension of time under 37 C.F.R. § 1.136(a)); and
    (5) the required papers must be filed via the EFS-Web.

    Additional information regarding the AFCP 2.0 program can be found on the Office's AFCP 2.0 webpage.

  • By Joseph Herndon —

    Federal Circuit SealNobel Biocare Services AG appealed from the decision of the U.S. Patent and Trademark Office's Patent Trial and Appeal Board in an inter partes review (IPR) holding claims 1–5 and 19 of U.S. Patent No. 8,714,977 invalid based on an ABT Catalog.  Many issues were presented, and here, we review the opinion with respect to whether the ABT Catalog qualifies as a prior art printed publication under pre-AIA 35 U.S.C. § 102(b).

    This case started on October 27, 2014, by Nobel filing a complaint with the U.S. International Trade Commission (ITC) for investigation of Instradent USA, Inc.'s Drive CM dental implants as allegedly violating 19 U.S.C. § 1337 by reason of importation of an implant product that infringes the '977 patent and U.S. Patent No. 8,764,443.  The ITC found claims of the '977 patent anticipated by an ABT "Product Catalog" with the date "March 2003" on the cover.  However, later, the ITC issued a Commission Opinion which determined that Instradent had failed to show by clear and convincing evidence that the ABT Catalog is prior art under § 102(b).

    In the interim, on August 20, 2015, Instradent petitioned for IPR of claims 1–7, 9, and 13–20 of the '977 patent with invalidity challenges based on the ABT Catalog.  The Board determined that a preponderance of the evidence establishes that the ABT Catalog qualifies as a prior art printed publication under pre-AIA 35 U.S.C. § 102(b), and ultimately found the claims invalid.

    Thus, the appeal largely turns on whether the ABT Catalog is prior art under § 102(b).

    The ABT Catalog

    In or about the early 1990s, named inventor Fromovich founded Alpha-Bio Tech Ltd. ("ABT"), which sold dental implants and related goods.  He also served as ABT's CEO.  In his capacity at ABT, Fromovich conducted dentist trainings and attended industry trade shows and conferences, including the International Dental Show (IDS) Conference held in Cologne, Germany.  At the IDS Conference, dental manufacturers would showcase their products and distribute written materials describing their products.  Nobel acquired ABT and its intellectual property rights in 2008.

    The ABT Catalog included a data of March 2003 on its cover and discloses dental implant screws and other details of implants as claimed in the '977 patent.  The ABT Catalog was produced by Instradent and alleged to be prior art to the '977 patent.

    Fromovich testified about the ABT Catalog during the ITC proceedings.  When asked why the catalog says "March 2003" on the cover, Fromovich indicated that he "estimated" it was because it was created in the end of March 2003 for the IDS in Cologne, Germany.  Fromovich testified that ABT had a small booth and he attended the March 2003 IDS Conference.  According to Fromovich, the IDS Conference is "one of the biggest for distribution in Europe" with possibly a thousand attendees.  He further testified that he did not recall if he brought the ABT Catalog to the conference, but that it was "unlikely."  He explained that if he brought the ABT Catalog, it would have been a "small amount" of catalogs because it would have been a first version of a 62-page document, and ABT did not send a shipment so it would have had to fit in his luggage.

    Fromovich also testified that the ABT Catalog was used in connection with training courses and provided to attendees without requiring them to sign a confidentiality agreement.

    The parties dispute whether the ABT Catalog qualifies as a "printed publication" under pre-AIA § 102(b).  Whether a reference qualifies as a "printed publication" is a legal conclusion based on underlying factual findings, and the underlying factual findings include whether a reference was publicly accessible.  The case law indicates that a reference will be considered publicly accessible if it was disseminated or otherwise made available to the extent that persons interested and ordinarily skilled in the subject matter or art exercising reasonable diligence can locate it.

    In addressing public accessibility of the ABT Catalog, the Board considered evidence that had been presented to the ITC, including Fromovich's testimony, and new evidence not considered by the ITC, including the declarations and deposition testimony of Yechiam Hantman and Zvi Chakir.  In March 2003, Hantman and Chakir coowned Chakir Implants, Ltd., a dental supply distributor located in Israel.  Hantman was unable to attend the conference, and he requested that Chakir collect catalogs from competitors at the 2003 IDS Conference and give them to him upon his return.  Hantman's declaration stated:  "Based upon my review of the attached materials and my specific recollections of conversations with customer [sic] in later 2002 and early 2003, and examination of the 2003 [ABT] Catalog after receiving it after the IDS trade show, I am certain that the 2003 [ABT] Catalog was publically accessible to the dental industry, including competitors, in March 2003, after the IDS show that year."

    Chakir's declaration stated that he collected catalogs and other materials from competitors, including ABT at the 2003 IDS Conference and gave the materials relating to dental implants to Mr. Hantman.

    The Federal Circuit found that substantial evidence supported the Board's finding that the ABT Catalog was publicly accessible prior to the critical date.  The Federal Circuit credited Chakir and Hantman's testimony that Chakir obtained a copy of the ABT Catalog at the March 2003 IDS Conference and that Hantman retained that copy in his records thereafter.  Hantman's declaration included excerpts of his copy of the ABT Catalog taken from his files.  The Board found that Hantman's copy of the ABT Catalog and the copy offered as prior art by Instradent in the IPR had identical pages except for some handwriting on the cover of Hantman's copy.  Nobel did not dispute this finding.

    Additionally, the ABT Catalog has the date "March 2003" on its cover.  Although the ABT Catalog's date is not dispositive of the date of public accessibility, its date is relevant evidence that supports the Board's finding of public accessibility at the March 2003 IDS Conference.

    Moreover, the Board found, and Nobel did not dispute on appeal, that the ABT Catalog is the type of document normally intended for public dissemination.  It is undisputed on appeal that the ABT Catalog is the type of document intended for public dissemination, and it bears no designations, such as "draft" or "confidential," that might suggest that it was not intended for public distribution.

    The Federal Circuit gave much weight to Chakir's testimony regarding his habitual practice in obtaining product literature, including brochures, at the IDS Conference.  Nobel's suggestion that Chakir could have obtained the ABT Catalog confidentially or under other circumstances that would not legally constitute public accessibility lacked any evidentiary basis.

    Additionally, Nobel pointed to no evidence that ABT ever distributed the ABT Catalog with an expectation that it would be kept confidential or not disseminated.

    The Federal Circuit addressed the sufficiency of the corroboration of the testimony and found the testimony of Messrs. Hantman and Chakir not only to be corroborated by each other, but also by a) the actual copy of the ABT Catalog, dated March 2003, submitted as evidence and b) Dr. Fromovich's testimony that ABT operated a booth at the March 2003 IDS conference.

    The fact that Hantman had a copy of the ABT Catalog in his files further corroborates his testimony that he obtained a copy of the same document asserted to be prior art in the IPR.

    Thus, although much of the evidence relied upon was based on testimony of biased witnesses regarding events that took place over 10-15 years ago, the Federal Circuit found no reason that the testimony was problematic.  As a result, the ABT Catalog was found to be prior art.

    Nobel Biocare Services AG v. Instradent USA, Inc. (Fed. Cir. 2018)
    Panel: Chief Judge Prost and Circuit Judges Lourie and Chen
    Opinion by Circuit Judge Lourie

  • EPO Becomes First Authority to Release Guidance Specific to Eligibility of AI/ML

    By Aaron Gin –

    EPOArtificial intelligence (AI) and machine learning (ML) are specifically addressed in new draft Guidelines for Examination (Guidance) released earlier this month from the European Patent Office (EPO).  The Guidance includes two new patentability-related subsections directed to 1) AI/ML; and 2) simulation, design or modeling.

    The Guidance first defines AI and ML as being "computational models and algorithms for classification, clustering, regression, and dimensionality reduction, [and which may include] neural networks, genetic algorithms, support vector machines, k-means, kernel regression, and discriminant analysis."  Additionally, the Guidance states that such computation models and algorithms relating to AI and ML are "per se of an abstract mathematical nature," indicating that the EPO will likely treat such algorithms as unpatentable by default.  This is further reinforced by the organizational structure of the new subsection, which appears as G(II)3.3.1 (AI and ML), falling under the mathematical methods exclusion G(II)3.3.

    Generally, under examination by the EPO, applications involving mathematical methods are excluded from patentability unless they are determined to have technical character under Art. 52(1).  In assessing whether a mathematical method possesses such technical character, a determination is made whether the invention produces a technical effect that serves a technical purpose.  A generic purpose such as "controlling a technical system" is not sufficient to confer technical character to the mathematical method.

    The Guidance specifically notes that "artificial intelligence and machine learning find applications in various fields of technology," and highlights examples of a "neural network in a heart-monitoring apparatus" and "classification of digital images, videos, audio or speech signals based on low-level features" as both possessing technical character.

    In contrast, the EPO identified the classification of text documents solely based on their textual content and classification of abstract data records without any indication of a particular technical use as not having technical purpose.  Furthermore, the EPO treats expressions such as "support vector machine", reasoning engine", or "neural network" as merely referring to abstract models that are "devoid of technical character."  Furthermore, the Guidance states that "even if [a] classification algorithm may be considered to have valuable mathematical properties," that alone is not per se a technical purpose.

    The new EPO Guidelines for Examination will go into effect on November 1, 2018, and are believed to represent the first official patent examination guidance to specifically address the eligibility of subject matter relating to AI and ML.  Going forward, it appears that such applications filed in the EPO should specifically highlight how a specific field of technology is improved by the AI-ML-related mathematical methods in order to best demonstrate technical character.

  • CalendarOctober 23, 2018 – "The State of 'Printed Publication' Prior Art Case Law: Practical Considerations for Patent Holders and Patent Challengers" (Strafford) – 1:00 to 2:30 pm (EDT)

    October 24, 2018 – Biopharma Patent Law (McDonnell Boehnen Hulbert & Berghoff LLP and Patent Docs) – 9:30 am to 1:00 pm, Cambridge, MA

    October 24, 2018 – "Preparing 'Diagnose & Treat' Patent Claims to be Valid and Enforceable" (Technology Transfer Tactics) – 1:00 to 2:00 pm (ET)

    October 24, 2018 – "How to Analyze Federal Circuit Opinions on Patent Law" (LexisNexis) – 3:30 to 4:30 pm (ET), Washington, DC

    October 24, 2018 – "Crisis Management for IP Lawyers & Their Clients — Trade Secrets and Reputation Risk Management" (Intellectual Property Law Association of Chicago Trade Secret and Unfair Competition Committee) – 3:00 to 4:00 pm (CT), Chicago, IL

    October 30, 2018 – "Obviousness Standard: Leveraging Latest PTO and Court Guidance — Overcoming Challenges of Obviousness and Attacks on Patent Validity" (Strafford) – 1:00 to 2:30 pm (EDT)

    October 30, 2018 – European biotech patent law update (D Young & Co) – 5:00 am, 8:00 am, and 1:00 pm (EDT)

    October 30, 2018 – "University Technology Transfer and Licensing Agreements — Determining Type of Transfer Agreement to Use, Structuring Key Provisions, Overcoming Unique Challenges" (Strafford) – 1:00 to 2:30 pm (EDT)

  • Strafford #1Strafford will be offering a webinar entitled "Obviousness Standard: Leveraging Latest PTO and Court Guidance — Overcoming Challenges of Obviousness and Attacks on Patent Validity" on October 30, 2018 from 1:00 to 2:30 pm (EDT).  William R. Reid and Jon L. Schuchardt of Dilworth IP will provide patent counsel with guidance on the evolving obviousness standard, including how the Federal Circuit's treatment of obviousness issues is changing, and how the Patent Trial and Appeal Board (PTAB) handles obviousness in the increasingly popular inter partes review (IPR) proceedings.  The webinar will review the following issues:

    • How have recent Federal Circuit decisions impacted application of the obviousness standard?
    • What level of "unexpected results" is needed to demonstrate patentability?
    • How can practitioners leverage recent decisions in which the Federal Circuit has insisted upon more thorough, reasoned explanations of the PTO's obviousness conclusions?
    • What strategies should patentees and petitioners employ to prevail on obviousness assertions in an IPR proceeding, and how will those strategies fare at the Federal Circuit?

    The registration fee for the webcast is $297.  Those interested in registering for the webinar, can do so here.